Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases... Show more
The RSI Oscillator for CYCN moved into overbought territory on September 09, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +18.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where CYCN advanced for three days, in 164 of 195 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
CYCN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 71 of 82 cases where CYCN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
The Momentum Indicator moved below the 0 level on September 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CYCN as a result. In 104 of 114 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CYCN turned negative on September 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 43 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
CYCN moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYCN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
a developer of pharmaceutical products for serious and orphan diseases
Industry Biotechnology